|
|||||
|
|
Failure of adefovir 20 mg to improve suboptimal response in lamivudine‐resistant hepatitis B patients treated with adefovir 10 mg and lamivudine |
|
| Authors: | M. Viganò P. Lampertico F. Facchetti G. Lunghi M. Colombo |
| Affiliation: | 1. “A. M. and A. Migliavacca” Center for Liver Disease, 1st Division of Gastroenterology, Department of Medicine, Fondazione IRCCS Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena, University of Milan, Milan, Italy;2. Division of Hygiene, IRCCS Fondazione Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena, Milan, Italy |
| Abstract: | Summary. Nine patients with lamivudine‐resistant chronic hepatitis B infection who had been treated with adefovir 10 mg/day and had had a suboptimal response but did not have genotypic resistance to adefovir were treated with high‐dose adefovir (20 mg/day). The response to the increased dose of adefovir was compared with the response in 15 patients with a suboptimal response who did not receive an increase in the dose of adefovir. The increase in the dose of adefovir did not lead to a significant reduction in hepatitis B DNA when compared with patients maintained on the standard dose. These data suggest that increasing the dose of adefovir in patients with a suboptimal response does not lead to an improved response. |
| Keywords: | adefovir dipivoxil antiviral treatment HBV DNA hepatitis B lamivudine resistance suboptimal response |